Teriparatide Research Guide

Full name: Teriparatide (PTH 1-34)

A recombinant fragment of parathyroid hormone (the first 34 amino acids) approved for osteoporosis. Unlike most bone drugs that only slow loss, teriparatide actively builds new bone, drawing interest for bone density and healing.

How Teriparatide Works

Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength.

Dosing Protocol

• Typical dose: 20 mcg once daily (medical)
• Frequency: Once daily
• Duration: Typically up to ~2 years (medical)
• Route: Subcutaneous injection

Reported Benefits

• Actively builds new bone
• Increases bone mineral density
• Reduces fracture risk (medical)
• Supports bone healing

Potential Side Effects

• Dizziness/orthostatic hypotension
• Nausea
• Leg cramps
• Elevated calcium
• Injection site reactions

Research Citations

1. Teriparatide reduces fracture risk (2016) - Significantly increased bone density and reduced vertebral and nonvertebral fractures versus placebo and antiresorptives.

Related Anti-Aging Compounds

• Epithalon - Full Profile
• NAD+ - Full Profile
• Humanin - Full Profile
• FOXO4-DRI - Full Profile
• SS-31 (Elamipretide) - Full Profile
• GDF-11 - Full Profile

View full Teriparatide profile with 3D molecule viewer →